首页> Cancer research communications> IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.

IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.

导出 LinkOut

翻译打印收藏纠错

第一作者： Zoë,Johnson

第一单位： iOnctura SA, Geneva, Switzerland.

作者： Zoë,Johnson ^[1] ; Chiara,Tarantelli ^[2] ; Elisa,Civanelli ^[2] ; Luciano,Cascione ^[3] ; Filippo,Spriano ^[2] ; Amy,Fraser ^[4] ; Pritom,Shah ^[4] ; Tyzoon,Nomanbhoy ^[5] ; Sara,Napoli ^[2] ; Andrea,Rinaldi ^[2] ; Karolina,Niewola-Staszkowska ^[1] ; Michael,Lahn ^[1] ; Dominique,Perrin ^[6] ; Mathias,Wenes ^[7] ; Denis,Migliorini ^[8] ; Francesco,Bertoni ^[9] ; Lars,van der Veen ^[1] ; Giusy,Di Conza ^[1]

作者单位： iOnctura SA, Geneva, Switzerland. ^[1] Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland. ^[2] Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.;SIB, Swiss Institute of Bioinformatics, Lausanne, Switzerland. ^[3] Cancer Research Horizons, Jonas Webb Building, Cambridge, United Kingdom. ^[4] ActivX Biosciences, Inc., La Jolla, California. ^[5] Merck Healthcare KGaA, Darmstadt, Germany. ^[6] Brain Tumor and Immune Cell Engineering Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Center for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.;Swiss Cancer Center Leman, Geneva and Lausanne, Switzerland. ^[7] Brain Tumor and Immune Cell Engineering Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Center for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.;Swiss Cancer Center Leman, Geneva and Lausanne, Switzerland.;Department of Oncology, Geneva University Hospitals (HUG), Geneva, Switzerland. ^[8] Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.;Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. ^[9]

医学主题词小鼠(Mice);动物(Animals);CD8阳性T淋巴细胞(CD8-Positive T-Lymphocytes);磷酸肌醇3-激酶类(Phosphatidylinositol 3-Kinases);肿瘤(Neoplasms);淋巴瘤(Lymphoma);免疫耐受(Immune Tolerance)

DOI 10.1158/2767-9764.CRC-22-0477

PMID 37066023

发布时间 2023-08-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cancer research communications

2023年3卷4期

576-591页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Cancer research communications

2023年3卷4期

576-591页

检索历史清除

IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.

Cancer research communications

相似文献

同项目论文

Cancer research communications

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.

Cancer research communications

相似文献

同项目论文

Cancer research communications

相关期刊

检索历史清除